Wilms tumor, also known as nephroblastoma, is the most common malignant renal tumor of childhood, typically arising in children under the age of five. It develops from embryonal kidney tissue that fails to mature properly, and in a small but significant proportion of patients it appears in both kidneys simultaneously. Bilateral disease presents a particular therapeutic dilemma: surgeons must balance the need to remove cancerous tissue against the imperative to preserve enough functioning kidney for a lifetime of renal health. It is precisely this tension that has shaped the modern treatment paradigm, in which chemotherapy is given first to shrink the tumors, allowing later surgery to be as kidney-sparing as possible.

The central tenet of that paradigm is that diagnosis in typical cases can be made on clinical and radiological grounds alone. The Children’s Oncology Group in North America and the SIOP Renal Tumour Study Group in Europe and beyond are the two cooperative bodies whose protocols govern nearly all contemporary Wilms tumor treatment. Both groups discourage routine diagnostic biopsy in children whose imaging findings are characteristic, permitting it only in narrowly defined exceptions such as tumors that behave atypically on scans or cases where the diagnosis is genuinely uncertain. Crucially, neither group recommends biopsy of bilateral disease at initial presentation, because the imaging appearance of bilateral masses in a young child is considered sufficiently specific to justify starting neoadjuvant chemotherapy without histological confirmation.

The rationale behind this approach is not merely administrative. Upfront nephrectomy or biopsy can rupture or seed tumor cells, upstage disease, and complicate later surgical planning. More fundamentally, any invasive procedure performed before chemotherapy begins introduces a window of potential morbidity during which the child receives no anti-cancer therapy. In the case described by Aujla, that window proved disastrous. The biopsy of the right kidney, sampled at an outside facility prior to referral, returned a non-diagnostic result, providing no useful information while breaching the renal architecture. The left-sided sample did confirm Wilms tumor, but at a cost that would soon become apparent.

Within a short time, the child developed a draining sinus at the right biopsy site, discharging pus persistently. Clinical evaluation and subsequent surgical exploration revealed the underlying cause: a pelviureteric fistula, an abnormal communication between the renal collecting system and the ureter that allowed urine to leak into the tissues, creating a nidus for infection. Cultures identified Escherichia coli, and the infection proved refractory to standard management. For an 18-month-old already facing bilateral kidney tumors, the complication transformed a straightforward treatment pathway into a prolonged ordeal, with both the start of neoadjuvant chemotherapy and the timing of definitive surgery pushed back significantly.

The case is a textbook illustration of why the cooperative groups have drawn such firm lines around biopsy. A needle traversing the kidney does not simply sample tissue; it can lacerate the collecting system, provoke bleeding, and open a channel between a normally sterile urinary tract and the skin. In centers with immediate pediatric surgical, urological, and infectious disease support, such complications are rare and manageable. In resource-constrained settings, where imaging guidance may be limited and referral pathways circuitous, the same procedure can produce complications that are difficult to diagnose and harder to fix. The report emphasizes that this biopsy was performed outside a specialized pediatric oncology center, a detail that recurs in discussions of avoidable harm in childhood cancer care across low- and middle-income countries.

Yet the guidelines are not absolute, and the report takes care to situate the case within a nuanced evidence landscape. Emerging data have supported the safety of image-guided biopsy in specific unilateral cases, particularly where imaging is atypical and the differential diagnosis includes entities such as renal cell carcinoma that would change the surgical plan entirely. Aujla’s analysis, however, warns against extrapolating those findings to bilateral tumors. The hemodynamics, anatomy, and therapeutic strategy of bilateral disease are different: the goal is maximal nephron preservation after chemotherapy response has been assessed, and the protocols have built in a mechanism for exactly that. Under the Children’s Oncology Group’s AREN0534 protocol, for example, selective biopsy is permitted later in the treatment course, guided by the patient’s response to initial chemotherapy and performed before definitive surgery, when it can genuinely inform the extent of resection rather than merely confirm what imaging already suggested.

The historical arc of Wilms tumor management explains how this consensus emerged. Early surgical series treated the tumor as a straightforward resection problem, and upfront nephrectomy was standard. The National Wilms Tumor Study Group in the United States and its European counterpart, which later evolved into the SIOP framework, demonstrated in successive randomized trials that preoperative chemotherapy in Europe, and carefully sequenced surgery and chemotherapy in North America, produced survival rates that now exceed ninety percent for localized disease. Along the way, the trials also catalogued the harms of unnecessary intervention, including tumor rupture at surgery and the staging consequences of preoperative procedures. Biopsy, once considered a reasonable diagnostic step, was progressively restricted as imaging quality improved and the characteristic appearance of nephroblastoma became reliably recognizable on ultrasound and computed tomography.

For pediatricians, who are typically the first clinicians to encounter a child with an abdominal mass, the practical lesson is one of restraint and rapid referral. The report notes that premature referral for biopsy or upfront nephrectomy remains a recurring error, often driven by the instinct that tissue diagnosis must precede cancer treatment. In Wilms tumor, that instinct is inverted: in a young child with bilateral renal masses and typical imaging, the protocol-compliant move is to refer immediately to a pediatric oncology center and begin chemotherapy, reserving tissue sampling for the defined scenarios in which it changes management. Every week spent pursuing a non-diagnostic biopsy is a week of untreated disease and, as this case shows, a week in which iatrogenic injury can compound the burden of malignancy.

The broader significance of the report lies in its setting. Low- and middle-income countries face a disproportionate share of global childhood cancer deaths, and the reasons are structural: late presentation, fragmented referral systems, limited access to specialized pathology and imaging, and well-intentioned interventions at facilities without pediatric oncology capability. Case reports like this one function as evidence for systems-level change, arguing for clear referral pathways, education of frontline providers about protocol-based management, and restraint in procedures that guidelines explicitly discourage. The child at the center of this report ultimately faced both her tumor and its man-made complications, her treatment delayed by an infection that should never have had a route into her urinary tract. Her story, documented with the consent of her guardians and published openly, adds a human dimension to a statistical consensus, reminding clinicians everywhere that in pediatric oncology, following the protocol is not bureaucratic caution but a safeguard measured in kidneys, in infections avoided, and in time that no child with cancer can afford to lose.

Subject of Research: Complications of guideline-discordant renal biopsy in a child with suspected bilateral Wilms tumor

Article Title: Guideline-discordant biopsy in suspected bilateral Wilms tumor and its surgical complications: a case report from a low-resource setting and review of current protocols

Article References: Aujla, R. (2026). Guideline-discordant biopsy in suspected bilateral Wilms tumor and its surgical complications: a case report from a low-resource setting and review of current protocols. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07680-y

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07680-y

Keywords: Wilms tumor, bilateral renal disease, pediatric oncology, renal biopsy, SIOP-RTSG, Children's Oncology Group, AREN0534, neoadjuvant chemotherapy, pelviureteric fistula, needle biopsy complications, low-resource settings, BMC Pediatrics